Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9375)	3/24/1999 11:42:00 PM
From: aknahow	Respond to of 17367

Duh, the company also wants to get the drug approved. XOMA not the FDA nor the DSMB set the mortality targets. They may have done it in consultation with the DSMB and needed the agreement of the FDA but XOMA calculated what the levels need to be. They would not have put zero in the treatment arm since that would expose them to ending the trial sooner and if deaths in the placebo arm were less than estimated and even only slightly higher in the treatment arm they would be screwed. So IMO they must have chosen a level of mortality for the treatment group that when compared to the level in the placebo group would give them a statistically significant level of efficacy. That does not mean there must be actual deaths in the treatment group, but only that with 186 in that arm I doubt there were zero deaths.